Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels

Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels

Abstract Rituximab (RTX) and cyclophosphamide (CYC) based treatments are both recommended as first-line therapies in idiopathic membranous nephropathy (IMN) by KDIGO 2021 guideline. However, the efficacy of RTX vs. CYC-based treatments in IMN is still controversial. We performed this systemic review...

Full description

Bibliographic Details
Main Authors: Cheng Xue, Jian Wang, Jinyan Pan, Congdie Liang, Chenchen Zhou, Jun Wu, Shuwei Song, Linlin Cui, Liming Zhang, Yawei Liu, Bing Dai
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Nephrology
Subjects:
Rituximab
Membranous nephropathy
Cyclophosphamide
Meta-analysis
Treatment
Online Access:https://doi.org/10.1186/s12882-023-03307-x

Internet

https://doi.org/10.1186/s12882-023-03307-x

Similar Items